Please cancel all pending claims 1-23 and add the following new claims.

24. A pharmaceutical composition, comprising:

(a) at least one polynucleotide, wherein the polynucleotide comprises a sequence of a binding site for a transcription factor and which is selected from the group consisting of
GATTGCCTGACGTCAGAGAG (SEQ ID NO:8),
GGAATGACGTTCCCTGTG (SEQ ID NO:9),
AGCTATGACGTTCCAAGG (SEQ ID NO:10),
GCTTGATGACTCAGCCGGAA (SEQ ID NO:11),
TCGATCGGGGCGGGGCGAGC (SEQ ID NO:12),
TGCAGATTGCGCAATCTGCA (SEQ ID NO:13),
AGCGGGGGCGAGCGGGGGCG (SEQ ID NO:14),
GTCCATTTCCCGTAAATCTT (SEQ ID NO:16),
TATGCATATTCCTGTAAGTG (SEQ ID NO:17),
CTGATTTCCCCGAAATGATG (SEQ ID NO:19),
AGATTTCTAGGAATTCAATC (SEQ ID NO:20),
GTATTTCCCAGAAAAGGAAC (SEQ ID NO:21),
AAGCGAAAATGAAATTGACT (SEQ ID NO:22), and
CAGGCATAACGGTTCCGTAG (SEQ ID NO:23); and

(b) a pharmaceutically acceptable carrier and/or diluent.

25. The pharmaceutical composition according to claim 24 further comprising at least one antigen.

26. The pharmaceutical composition according to claim 24 characterized in that the polynucleotide comprises at least one phosphorothioate linkage.

27. The pharmaceutical composition according to claim 25, wherein the antigen is selected from the group consisting of peptides, polypeptides, proteins, polysaccharides, steroids, tumor cell antigens, and tumor cells.

28. The pharmaceutical composition according to claim 24, wherein the binding site for a transcription factor is a binding site for a transcription factor of a cytokine.

29. The pharmaceutical composition according to claim 28, wherein the sequence is selected from the group consisting of SEQ ID NO:9 and SEQ ID NO:10.

30. A method of modulating an immune response, comprising

contacting an immune cell with an antigen and at least one polynucleotide, wherein the polynucleotide comprises a sequence of a binding site for a transcription factor and which is selected from the group consisting of

GATTGCCTGACGTCAGAGAG (SEQ ID NO:8),
GGAATGACGTTCCCTGTG (SEQ ID NO:9),
AGCTATGACGTTCCAAGG (SEQ ID NO:10),
GCTTGATGACTCAGCCGGAA (SEQ ID NO:11),
TCGATCGGGGCGGGGCGAGC (SEQ ID NO:12),
TGCAGATTGCGCAATCTGCA (SEQ ID NO:13),
AGCGGGGGCGAGCGGGGGCG (SEQ ID NO:14),
GTCCATTTCCCGTAAATCTT (SEQ ID NO:16),
TATGCATATTCCTGTAAGTG (SEQ ID NO:17),
CTGATTTCCCCGAAATGATG (SEQ ID NO:19),
AGATTTCTAGGAATTCAATC (SEQ ID NO:20),
GTATTTCCCAGAAAAGGAAC (SEQ ID NO:21),
AAGCGAAAATGAAATTGACT (SEQ ID NO:22), and
CAGGCATAACGGTTCCGTAG (SEQ ID NO:23),

wherein the polynucleotide is capable of modulating the immune response to the antigen.

31. The method according to claim 30, wherein the antigen is selected from the group consisting of peptides, polypeptides, proteins, polysaccharides, steroids, tumor cell antigens, and tumor cells.

32. The method according to claim 30, wherein the polynucleotide comprises at least one phosphorothioate linkage.

33. The method according to claim 30, wherein the modulating is selected from the group consisting of breaking immune tolerance, regulating Th1/Th2 helper cell responses, switching immunoglobulin classes, treating autoimmune diseases, and inducing tolerance.

34. The method of claim 30, wherein the polynucleotide is capable of inducing a cytolytic T lymphocyte response.

35. The method of claim 34, wherein the polynucleotide comprises a sequence selected from the group consisting of
GATTGCCTGACGTCAGAGAG (SEQ ID NO:8),
GGAATGACGTTCCCTGTG (SEQ ID NO:9),
AGCTATGACGTTCCAAGG (SEQ ID NO:10),
TCGATCGGGGCGGGGCGAGC (SEQ ID NO:12),
GTCCATTTCCCGTAAATCTT (SEQ ID NO:16),
CTGATTTCCCCGAAATGATG (SEQ ID NO:19),
GTATTTCCCAGAAAAGGAAC (SEQ ID NO:21),
AAGCGAAAATGAAATTGACT (SEQ ID NO:22), and
CAGGCATAACGGTTCCGTAG (SEQ ID NO:23).

36. The method of claim 30, wherein the polynucleotide is capable of inducing a Th2 immune response.

37. The method of claim 36, wherein the polynucleotide comprises a sequence selected from the group consisting of
GATTGCCTGACGTCAGAGAG (SEQ ID NO:8),
GTCCATTTCCCGTAAATCTT (SEQ ID NO:16), and
CTGATTTCCCCGAAATGATG (SEQ ID NO:19).

38. The method of claim 30, wherein the polynucleotide is capable of inducing a Th1 immune response.